Ipsen S.A. (EPA:IPN)
France · Delayed Price · Currency is EUR 123.10
-1.00 (-0.81%)
Nov 5, 2025, 5:35 PM CET
Ipsen Revenue
Ipsen had revenue of 1.94B EUR in the half year ending June 30, 2025, with 19.35% growth. This brings the company's revenue in the last twelve months to 3.76B, up 11.54% year-over-year. In the year 2024, Ipsen had annual revenue of 3.57B with 8.11% growth.
Revenue (ttm)
3.76B
Revenue Growth
+11.54%
P/S Ratio
2.69
Revenue / Employee
701.72K
Employees
5,358
Market Cap
10.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.57B | 268.10M | 8.11% |
| Dec 31, 2023 | 3.31B | 150.00M | 4.75% |
| Dec 31, 2022 | 3.16B | 407.80M | 14.84% |
| Dec 31, 2021 | 2.75B | 62.40M | 2.32% |
| Dec 31, 2020 | 2.69B | -6.60M | -0.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Sartorius Stedim Biotech | 2.95B |
Ipsen News
- 14 days ago - Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Ipsen S.A. 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 14 days ago - Ipsen S.A. reports Q3 results; upgrades FY outlook - Seeking Alpha
- 6 weeks ago - Ipsen Reports Positive Phase II Data For IPN10200 In Glabellar Lines, Shows Long-Lasting Efficacy - Nasdaq
- 6 weeks ago - Ipsen Secures Japanese Approval For Bylvay In Treating Pruritus - Nasdaq
- 2 months ago - Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome - Benzinga
- 2 months ago - Ipsen S.A. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) - GlobeNewsWire